Larvol Delta - A-Safety-Efficacy-and-Pharmacokinetic-PK-Study-of-HBI002-an-Oral-Carbon-Monoxide-CO-Therapeutic-in-Subjects-With-Sickle-Cell-Disease-SCD

carbon monoxide (HBI-002) - Hillhurst Biopharma

http://clinicaltrials.gov/ct2/show/NCT06144749

Mar 26, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next